The asialoglycoprotein receptor (ASGPr) on hepatocytes plays a role in the clearance of desialylated proteins from the serum. Although its sugar preference (N-acetylgalactosamine (GalNAc) >> galactose), and the effects of ligand valency (tetra-> tri->> di->> monoantennary) and sugar spacing (20 Å >> 10 Å >> 4 Å) are well-documented, the effect of particle size on recognition and uptake of ligands by the receptor is poorly defined. In the present study, we assessed the maximum ligand size that still alllows effective processing by the ASGPr of mouse hepatocytes in vivo and in vitro. Hereto, we synthesized a novel glycolipid, which possesses a highly hydrophobic steroid moiety for stable incorporation into liposomes, and a triantennary GalNAc 3 -terminated cluster glycoside with a high nanomolar affinity (2 nM) for the ASGPr. From these data we conclude that, in addition to the species, valency, and orientation of sugar residues, size is also an important determinant for effective recognition and processing of substrates by the ASGPr. Therefore, these data have important implications for the design of ASGPr-specific carriers that are aimed at hepatocyte-directed delivery of drugs and genes.
INTRODUCTION

4
shown that optimal receptor recognition of synthetic cluster glycosides is also determined by appropriate spacing (at least 15 Å) of the sugar residues.
Although the effects of sugar type and valency on the affinity of ligands for the ASGPr are now well-established, the effects of ligand size on the binding characteristics to the receptor have still not been fully mapped. Early in vivo studies suggested that the ASGPr is mainly responsible for the uptake of small (≤ 15 nm) particles exposing galactose at relatively low density, such as high density lipoproteins (HDL) that are lactosylated (21) or provided with galactose-terminated monoantennary (mono-gal-chol) (22, 23) and triantennary glycolipids (trisgal-chol) (24), and galactose-exposing gold particles (25). In contrast, the GPr predominantly recognizes larger galactose-exposing particles (> 15 nm) (26-28), such as desialylated rat erythrocytes (29, 30), low density lipoproteins (LDL) that are lactosylated (26) or provided with mono-gal-chol (22, 23) and tris-gal-chol (31), and tris-gal-chol-exposing liposomes (31). The affinity of glycosides for the GPr was shown to increase with particle size to reach a maximum at 15 nm (27). Furthermore, it has been shown that the GPr preferentially recognizes a high density of either fucose or galactose on either proteins (13, 15) and particles (26, 32) .
In contrast to these findings, providing LDL with lactosaminated Fab fragments of antiapoB100 antibodies induces a high uptake of LDL by the ASGPr in vivo (33) . We have also recently shown that even larger (30 nm-sized) liposomes may also be specifically taken up by 7 Synthesis and Characterisation of Glycolipids -The synthesis of the ether-linked triantennary galactoside Z-Gly-TRIS(Gal) 3 (Gal 3 ; M w 1484) and its γ-aminobutyric acid (GABA)-mediated coupling product with the steroid structure 3α-oleoyloxy cholenic acid, leading to the bifunctional glycolipid (3α(oleoyloxy)-5ß-cholanoyl)-GABA-Gly-TRIS(Gal) 3 (LCO-Gal 3 ; M w 2058) (Fig. 1A) has been recently reported in full detail (32) . A novel triantennary N-acetylgalactosamineterminated cluster (Z-TRIS(GalNAc) 3 ; M w 1532) has been synthesized and conjugated with a nearly identical steroid structure via a tyrosine residue, to allow for trace labeling with 125 I, yielding (3ß(oleoylamido)-5ß-cholanoyl)-Tyr-Gly-TRIS(GalNAc) 3 (LCO-Tyr-GalNAc 3 ; M w 2182) (Fig. 1B) . The synthesis of this glycolipid will be described in full detail elsewhere. The homogeneity and identity of both glycolipids has been fully established by HPLC, NMR spectroscopy, and mass spectroscopy. The freeze-dried glycolipids were dissolved in PBS at a final concentration of 25-50 µg/µl and stored at -80°C under argon before use. Their stability (which exceeded 12 months) was routinely checked by thin-layer chromatography (n-butanol: npropanol: 25% NH 4 In Vitro Binding to Hepatocytes -Hepatocytes were isolated from anesthetized rats or mice by perfusion of the liver with collagenase (type IV, 0.05% (w/v)) for 10 min at 37°C according to the method of Seglen (47) as detailed earlier (27). The cells were ≥ 99% pure as judged by light microscopy and their viabilities were ≥ 95% (rat) and ≥ 80% (mouse) as determined by 0.2% trypan blue exclusion. Hepatocytes were incubated (2 h at 4°C) in DMEM containing 2% BSA (1   x 10 6 cells/ml) with 5 nM 125 I-ASOR in the presence of increasing amounts of unlabeled galactose (0.2-200 mM), Z-Gly-TRIS(Gal) 3 (1-1000 nM), or Z-Tyr-Gly-TRIS(GalNAc) 3 FCS ( Subsequently, the cells were washed twice with DMEM + 2% BSA to remove unbound particles, and (intra)cellular localisation of DiO and DiI was visualized during further incubation at 37°C. 
In Vitro Association of Radioactively Labeled Liposomes with Mouse Hepatocytes
RESULTS
Affinity of GalNAc-Terminated Triantennary
Cluster for the Hepatic ASGPr -We determined the affinity of the newly synthesized triantennary Gal-terminated cluster glycoside Z-Gly-TRIS(Gal) 3 ( Fig. 1A ) and the GalNAc-terminated cluster glycoside Z-Gly-TRIS(GalNAc) 3 Replacement of Gal by GalNAc in Z-Gly-TRIS(GalNAc) 3 caused a further 50-fold increased affinity (2.1±0.3 nM and 2.7±1.0 nM towards rat and mouse hepatocytes, respectively), which is in agreement with observations from Lee et al. (37, 38) .
Interaction of Glycolipids with Liposomes -To investigate the interaction of LCO-Tyr-GalNAc 3
with the differently sized EYPC:CO liposomes, we first examined the effect of the glycolipid on the electrophoretic pattern of the liposomes (Fig. 3) . Incubation of 30 nm-sized liposomes with radioiodinated glycolipid resulted in an LCO-Tyr-GalNAc 3 concentration-dependent reduction of the electrophoretic mobility of the liposomes (R f 0.18±0.01) (Fig. 3A) . Incorporation of the glycolipid was evidenced by comigration of the radiolabeled glycolipid with the liposomes ( (Fig. 4B) , indicating that the glycolipid firmly associates with the particles due to its highly hydrophobic moiety, and does not readily redistribute to serum lipoproteins. The increased serum clearance of the liposomes was mainly caused by uptake by the liver, which was dose-dependently enhanced via 31.2±3.0% (1%, w/w; P < 0.05) to 65.1±0.3% (5%, w/w; P < 0.0001) of the injected dose at 30 min after injection (Fig. 4) .
The effect of the 50-fold higher ASGPr affinity of LCO-GalNAc 3 as compared to LCOGal 3 on the extent of the glycolipid-induced liver uptake of the 30 nm-sized liposomes was addressed by determining the liver uptake of liposomes after incubation with increasing amounts of both glycolipids (Fig. 5) . A differential effect of the glycolipids on total liver uptake of the liposomes could predominantly be detected at low incorporation levels. Whereas at 1%
(w/w) LCO-Gal 3 did not affect the liver uptake, indicating that a threshold loading of liposomes is necessary for inducing affinity for the liver, a 4-fold increased uptake (P < 0.05) could already be detected using the same amount of LCO-Tyr-GalNAc 3 .
Although the effect of the increased ASGPr affinity of LCO-Tyr-GalNAc 3 on the total uptake of liposomes by the liver may be limited, a large effect was observed on the ASGPr specificity of the liposomes. This was determined by a preinjection of ASOR, which specifically blocks ASGPr-mediated uptake by hepatocytes, but not GPr-mediated uptake by Kupffer cells (24, 31). At low amounts of LCO-Gal 3 (≤ 5%, w/w), the glycolipid-induced liver uptake could be completely blocked by a preinjection of ASOR. However, at higher LCO-Gal 3 concentrations, the effect of ASOR on the induced uptake rapidly declined, indicating an almost complete shift in uptake from hepatocytes to Kupffer cells at 50% (w/w). This can be explained by a high surface density of galactose residues that are readily recognized by the GPr (26, 32) (Fig. 5A ). In contrast, preferential uptake of the liposomes by the ASGPr was observed even at high LCOTyr-GalNAc 3 concentrations, since a high degree of inhibition (i.e. 62%) of the liver uptake by the ASGPr competitor could still be detected at 50% (w/w) (Fig. 5B) . Apparently, the very high affinity of LCO-Tyr-GalNAc 3 for the ASGPr overrules the stimulating effect of a high glycoside surface density on the induced uptake by the GPr.
Size-Dependent Association of Liposomes to the ASGPr in Mice -Since it is now evident that
LCO-Tyr-GalNAc 3 is superior to LCO-Gal 3 in its capacity to selectively stimulate the ASGPrmediated uptake of liposomes in vivo, LCO-Tyr-GalNAc 3 (5% w/w) was used to evaluate the effect of liposomal size on the ASGPr-mediated uptake by hepatocytes (Fig. 6 ). As expected from the size-dependent enhanced affinity of liposomes for the reticuloendothelial system, both the hepatic and splenic uptake of the ligand-deficient liposomes increased with increasing liposomal diameter. LCO-Tyr-GalNAc 3 was able to induce the liver uptake of liposomes irrespective of their size, although the extent of liver uptake slightly decreased with increasing particle size. Importantly, the glycolipid-induced liver uptake of 30, 55, and 70 nm-sized particles (prepared by sonication) could be almost completely blocked by preinjection of ASOR, indicating that the uptake is fully mediated by the ASGPr. In contrast, although the liver association of the 90 nm-sized liposomes (prepared by extrusion) also seemed to be enhanced by LCO-Tyr-GalNAc 3 , ASOR was unable to compete for the liver uptake, indicating that the ASGPr is not involved (Fig. 6 ). The inability of ASOR to block the glycolipid-induced liver uptake of these large liposomes can not be ascribed to an increased affinity of these liposomes for the 
Size-Dependent Uptake of Liposomes by the ASGPr on Hepatocytes -The in vivo results point
to the existence of a particle size limit (< 90 nm) below which liposomes still can associate with the hepatic ASGPr. Since this diameter concurs with the size of the fenestrae that are present in the sinusoidal endothelium of the liver (approx. 100 nm) (52), we subsequently evaluated whether this physiological barrier may have contributed to the observed size effects in vivo.
Therefore, liposomal uptake experiments were performed using freshly isolated mouse hepatocytes in vitro ( Fig. 7 and 8 ).
To quantify the association of the liposomes via the ASGPr on hepatocytes in vitro,
hepatocytes were incubated with [ 3 H]CO-labeled particles (Fig. 7) . The glycolipid-deficient 30, 50, and 70 nm-sized liposomes showed a time-dependent association with the hepatocytes Binding and uptake of the liposomes was markedly inhibited in the presence of 100 mM GalNAc or in the absence of the glycolipid (data not shown).
DISCUSSION
So far, the ligand recognition by the ASGPr has been well-characterised with respect to sugar preference (GalNAc >> Gal) (7-9), optimum ligand valency (tetra-> tri->> di->> monoantennary) (8, 18) Taking advantage of the above-mentioned 'affinity rules', we have synthesized the triantennary glycoside Z-TRIS(GalNAc) 3 with a nanomolar affinity for the ASGPr (K i 2 nM). This affinity is similar to that of the triantennary glycopeptides YEE(GalNAcAH) 3 and YDD(G-ahGalNAc) 3 that have been developed by Lee et al. (37, 38) , and utilized for ASGPr-directed delivery of DNA (54) and oligodeoxynucleoside methylphosphonates (55) . To establish firm association with liposomes, the glycoside was coupled to lithocholic oleate, which has already been shown to confer a stable incorporation of antisense oligodeoxynucleotides (36),
anthracyclines (56), and glycosides (32) into lipidic particles. Also in this study, a tight association of the Gal 3 and GalNAc 3 -terminated glycolipids with the liposomes was observed, withstanding dissociation in the blood. Unlike the previously applied cholesterol-coupled glycosides, which induced a biphasic serum decay of lipoproteins as explained by partial glycolipid-induced clearance of injected lipoproteins by the liver in the α-phase, followed by redistribution of glycolipid over the endogenous lipoprotein pool in the ß-phase (23, 24, 53), the present glycolipids induced a monophasic clearance of liposomes from the serum upon intravenous injection. The differences between both glycolipids with respect to the lipophilic moiety, the absence or presence of a a Tyr moiety, and the sugar type (Gal or GalNAc) apparently do not affect the association of the glycolipid with the liposomes.
As a result of the 50-fold higher ASGPr affinity of the GalNAc 3 -terminated glycolipid over the Gal 3 -terminated glycolipid, an effective targeting of 30 nm-sized liposomes to the ASGPr could already be accomplished at concentrations as low as 1% (w/w), at which the Gal 3 -terminated glycolipid had no effect. This amount corresponds to only 36 glycolipid molecules per particle, assuming 7.62x10 13 liposomes per mg of phospholipid (39) . When taking into account that 60% of the phospholipids are located in the outer phospholipid layer (39) , it thus appears that approx. 22 molecules of the GalNAc 3 -terminated glycolipid are sufficient for inducing uptake of liposomes by the ASGPr. The most prominent effect of the higher affinity for the ASGPr, however, involves the considerably enhanced specificity of liposomes for the ASGPr as opposed to the GPr over a wide glycolipid loading range (1-50%, w/w). It can be calculated that at an incorporation of 50% (w/w) of glycolipid, the glycoside occupies only a very restricted surface area (approx. 3 nm 2 ) (32). In this case, the conformational properties of the individual clusters of the Gal 3 -terminated glycolipid, which are of vital importance for high-affinity recognition by the ASGPr, may be overruled by the high overall Gal density on the liposomal surface, that has been shown to lead to efficient uptake by the GPr on Kupffer cells (27).
Apparently, the preferential uptake of liposomes provided with an equal concentration (i.e. 50%, w/w) of the GalNAc 3 -terminated glycolipid by hepatocytes indicates that, in contrast to Gal clusters, a similarly high density of GalNAc clusters on the particle surface does not impair the specificity for the ASGPr. Therefore, the GalNAc 3 -exposing glycolipid is very suitable for evaluation of the effect of particle size on recognition and uptake by the ASGPr in vivo and in vitro. These findings have also important implications for research on liposome-mediated ASGPr-directed drug delivery to hepatocytes. Although galactose is generally utilized as a recognition marker for the ASGPr (e.g. 57) , the present data demonstrate that the specificity for this receptor in vivo may be greatly improved by the application of the ligand GalNAc instead.
The hepatic and splenic uptake of the glycolipid-deficient liposomes appeared to be enhanced with increasing particle size. Since an opposite effect was observed with respect to the uptake of glycolipid-deficient liposomes by isolated hepatocytes (30-70 nm versus 90 nm), and given the fact that the affinity of particulate carriers for the reticuloendothelial system increases with increasing particle size, it is likely that this size dependent (glycolipidindependent) liver uptake is exerted by Kupffer cells. At a load of 5% (w/w), the GalNAc 3 -exposing glycolipid did not stimulate the uptake of liposomes by macrophages in general and splenic macrophages in particular, although C-type Gal/GalNAc-recognizing receptors have been described on extrahepatic macrophages from rats and mice (58-62) in addition to S-type (soluble) Ca 2+ -independent galactoside-binding proteins (galaptins, galectins) (63, 64). Possibly, the macrophage asialoglycoprotein binding protein displays a lower affinity towards GalNAc than Gal and lacks the cluster effect that has been observed for the ASGPr (65). Similarly, galectins have been shown to have minimal affinity for triantennary cluster galactosides as compared to C-type lectins (63, 64, 66).
Using LCO-Tyr-GalNAc 3 at a load of 5% (w/w), it appeared that liposomes with a size up to 70 nm are effectively recognized by the ASGPr on hepatocytes in vivo, whereas the 90-nm particles did not associate with the ASGPr. This phenomenon is not caused by the physical barrier raised by the fenestrated endothelium that shields hepatocytes from the circulation, as similar findings were obtained from liposome uptake experiments by isolated hepatocytes in vitro. It is unlikely that these observations are related to a restricted size limit of endosomes formed after ASGPr-mediated endocytosis via clathrin-coated pits, as the average endosome size in mammalian hepatocytes has been reported to be 100 nm (67), with a wide size distribution of 50-350 nm (68). Moreover, as compared to the 30-70 nm-sized particles, the 90 nm-sized liposomes already displayed an impaired binding to isolated hepatocytes. Taking into account that the ASGPr is predominantly diffusely, and perhaps inaccessibly, distributed within the microvilli clefts at the sinusoidal hepatocyte surface (69-71), it is tempting to assume that penetration of particles between the microvilli may be a limiting factor for ASGPr-mediated uptake, but this possibility can not be conclusively established from the current experimental set up. Regardless of the precise mechanism, our present data may explain why earlier attempts to efficiently target relatively large liposomes to the ASGPr on hepatocytes have not been successful. For example, the observation that 100 nm-sized liposomes provided with (monoantennary) polyethyleneglycol-coupled galactolipids were mainly taken up by Kupffer cells (57) may not only be explained by lack of ASGPr specificity, but also by their unfavorable dimensions.
In conclusion, in addition to the sugar preference and cluster effect, we have further elucidated the ligand recognition characteristics of the ASGPr, by demonstrating that effective binding and internalisation by the receptor is restricted to glycoside-exposing particles with a diameter ≤ 70 nm, whereas larger particles are not recognized. Due to its unique localisation, abundance, and high internalisation capacity, the ASGPr is widely used as a target for the specific delivery of genes and therapeutic agents to hepatocytes. Therefore, our findings also have important implications for the design of such non-viral gene vectors and drug targeting vehicles with respect to sugar ligand (GalNAc >> Gal) and particle size (≤ 70 nm). GalNAc, N-acetylgalactosamine; GPr, galactose particle receptor; LCO-Gal 3 , (3α(oleoyloxy)-5ß-cholanoyl)-GABA-Gly-TRIS(Gal) 3 ; LCO-Tyr-GalNAc 3 , (3ß(oleoylamido)-5ß-cholanoyl)-GABATyr-Gly-TRIS(GalNAc) 3 ; PBS, phosphate-buffered saline. 
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